"Can Eli Lilly Become the First $1 Trillion Pharma Stock on Weight Loss Boom?"
TL;DR Summary
Morgan Stanley is considering the possibility of Eli Lilly becoming the first pharmaceutical company to reach a market value of $1 trillion, driven by the potential success of its experimental weight loss drug. The investment firm believes that the drug, known as tirzepatide, could generate significant revenue and propel Eli Lilly's stock to new heights in the future.
- Morgan Stanley ponders if Eli Lilly could be the first $1 trillion pharma stock on weight loss boom CNBC
- Lilly Stock’s Upside Prompts Morgan Stanley to Ask if It Can Reach $1 Trillion Barron's
- (LLY) Lilly Closer to Joining Magnificent Seven in $1 Trillion Market Cap Club Bloomberg
- Will Weight-Loss, Diabetes Drugs Drive LLY Stock Into $1 Trillion Club? Investor's Business Daily
- Lilly's Climb Has Morgan Stanley Asking $1 Trillion Question Yahoo Finance
Reading Insights
Total Reads
0
Unique Readers
8
Time Saved
0 min
vs 1 min read
Condensed
-729%
7 → 58 words
Want the full story? Read the original article
Read on CNBC